Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems

Definitions

• ABSTRACT Compounds of the class of 3-(5-nitro-2-furyl)- 1H- pyrazolo[3,4-d]pyrimidin-4(5l-l)-one have antimicrobial properties and are active ingredients in pharmaceutical compositions and animal feedstuff compositions, an illustrative example is 1,6-dimethyl-3-(5- 6 Claims, No Drawings 3-(5-NITRO-2-FURYL)- I H- PYRAZOLO[ 3 ,4 ]PYRIMIDlNS-4( SID-ONES DETAILED DESCRIPTION
• the present invention relates to nitrofuryl derivatives, in particular, to derivatives of 3-(5-nitro-2-furyl)- II'I-pyrazolo[3,4-d]pyrimidin-4(5I-I)-one which compounds have antimicrobial properties.
• compositions containing these compounds relate to pharmaceutical and animal feedstuff compositions containing these compounds and to methods for the treatment of mammals suffering from microbial infections, particularly of urinary tract infections, comprising administering to said mammals an effective amount of such compound.
• the invention also provides methods for protecting organic material susceptible to microbial attack with an effective amount of a compound according to the invention.
• the present invention relates to compounds of the formula I wherein R is alkyl having from one to five carbon atoms or carbalkoxy having from one to five carbon atoms in the alkyl moiety, and
• R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted partially or completely by chlorc; or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, aralkyl having up to 12 carbon atoms, or alkenyl having from two to four carbon atoms.
• alkyl groups having from one to five carbon atoms are methyl, ethyl, n-propyl, isopropyl, nbutyl, tertiarybutyl and n-pentyl groups.
• R as an alkyl group contains from one to three carbon atoms.
• Cycloalkyl of from five to seven carbon atoms embraces cyclopentyl, cyclohexyl and cycloheptyl' groups, whereby the cyclohexyl group is preferred.
• aralkyl is meant for example the benzyl group and other groups consisting of an aryl and an alkyl moiety, such as phenylethyl, naphthylmethyl and the like.
• Alkenyl containing from two to four carbon atoms embraces the vinyl, allyl, 2-methallyl, but-2-enyl and but- 3-enyl group.
• R, R and R are as herein before defined, which is cyclised without isolation.
• This reaction may be carried out directly between the compound II and the selected reagent, or may be carried out in the presence of an inert solvent, such as for example dimethylsulphoxide or dimethylformamide.
• an inert solvent such as for example dimethylsulphoxide or dimethylformamide.
• the presence of an inert solvent is of course desirable if the compound II is a solid. In all cases, the reaction will preferably be carried out at a temperature of from C. to the reflux temperature of the reaction mixture.
• a compound of the general formula II may be reacted with a carboxylic acid derivative R COX or (R CO) O where R is as previously defined and X is hydroxyl, halogen (preferably chlorine or bromine), amino, or the grouping -OR where R, is an alkyl or alkenyl group containing from one to.
• the nitrofuryl-nitrilimine of formula X may conveniently be generated, as required, during the course of the reaction with malononitrile, by treating with a base the corresponding nitrofuryl-a-halo-hydrazone having the formula XI Nun, (xi)
• the process may, if desired, be effected in the presence of a conventional base or other hydrogen halide acceptor.
• the halogen present in the halohydrazone of for mula Xl is preferably chlorine or bromine.
• the compounds of the invention have valuable anti microbial properties, and in particular have antibacterial, antimycoplasmal, anthelminthic, antiprotozoal, coccidiostatic, trypanocidal and antimalarial activity of value in human or veterinary medicine.
• the compounds are particularly valuable in the treatment of infections of the intestinal and urinary tracts.
• the active compounds are administered in dosages depending on the kind of infection, the species and the age, weight and particular condition of the individual being treated. in general the daily dosage upon oral application will vary from about 1 to lOO mg kg for mammals.
• the compounds may also be used to protect a high molecular weight hydrophobic or other organic material susceptible to bacterial or other microbial deterioration by contacting the organic material with, impregnating in or otherwise treating with, the compounds in amounts up to about 5 percent by weight.
• the compounds also find application as growth-promoting additives to animal feedstuffs, to which they may be added in proportion of from 5 to 500 parts per million.
• the invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising an antimicrobially effective proportion of an active compound of the invention and a pharmacologically acceptable solid carrier or liquid diluent.
• compositions according to the invention contain at least one active compound of the invention as active substance together with a conventional pharmaceutical carrier.
• a conventional pharmaceutical carrier for external use, for example in disinfecting healthy skin, disinfecting wounds and in treating dermatoses and affections of the mucous membranes caused by bacteria, ointments, powders and tinctures are used in particular.
• the ointment bases may be anhydrous, for instance they can consist of mixtures of wool fat and soft paraffin, or they can consist of aqueous emulsions in which the active substance is suspended.
• Suitable carriers for powders are, for instance, rice starch and other starches; the bulk weight of the carriers may be made lighter, if desired, for example by adding highly dispersed silicic acid, or may be made heavier by adding talcum.
• the tinctures may contain at least one active ingredient in aqueous ethanol, in particular 45 to percent ethanol, to which 10 to 20 percent of glycerol may be added, if desired. Solutions prepared from polyethylene glycol and other conventional solubility promoters, and also, optionally, from emulsifying agents, may be used with particular advantage in disinfecting healthy skin.
• the content of active ingredient in pharmaceutical compositions for external application is preferably in the range of from 0.1 to 5 percent.
• Gargles or concentrates for their preparation, and tablets for slow dissolution in the mouth are suitable for the disinfection of the mouth and throat.
• the former are preferably prepared from alcoholic solutions containing 1 to 5 percent of active substance to which glycerol or flavourings may be added.
• Lozenges that is solid dosage units, preferably have a relatively high content of sugar or similar substances and a relatively low content of active substance, for instance 0.2 to 20 percent by weight, as well as the usual convential additives such as binding agents and flavourings.
• Solid dosage units in particular tablets, dragees (sugar coated tablets) and capsules, are convenient for use in intestinal disinfection and for the oral treatment of urinary tract infections. These units preferably contain from to 90 percent of the active compound to enable the administration of daily doses of from 0.1 to 2.5 grams to adults, or of suitable reduced doses to children to be made. Tablets and dragee cores are produced by combining the active compounds with solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or polyethylene glycols of suitable molecular weight.
• solid, pulverulent carriers such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatines, preferably with the addition of lubricants such as magnesium or calcium stearate or
• Dragee cores may then be coated, for example with concentrated sugar solutions which can also contain gum arabic, talcum and/or titanium dioxide, or they may be coated with a lacquer dissolved in volatile organic solvents or mixture of solvents.
• Dyestuffs can be added to these coatings, for instance to differentiate between varying dosages.
• Soft gelatine capsules and other closed capsules consist, for example, of a mixture of gelatines and glycerol and may contain, for example, mixtures of the active compound with polyethylene glycol.
• Hard gelatine capsules contain, for example, granulates of an active substance with solid pulverulent carriers, for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatines, and magnesium stearate or stearic acid.
• solid pulverulent carriers for instance lactose, saccharose, sorbitol, mannitol, starches (such as potato starch, maize starch or amylopectin), cellulose derivatives of gelatines, and magnesium stearate or stearic acid.
• the active compounds can be present as solo active ingredients or they can also be combined with other known pharmacologically active, and especially antibacterial and/or antimycotically or other anti-microbially active substances, for example to broaden the range of application. They can be combined for example, with 5,7-dichloro-2-methyl-8- quinolinol or other derivatives of 8-quinolinol, with sulfamerazine or sulfafurazole or other derivatives of sulfanilamide, with chloramphenicol or tetracycline or other antibiotics, with 3,4.,5-tribromosalicylanilide or other halogenated salicylanilides, with halogenated carbanilides, with halogenated benzoxazoles or benzoxazolones, with polychloro-hydroxydiphenylrnethanes, with halogen-di-hydroxy-diphenyl sulphides, with 4,4'-dichloro-2-hydroxydiphenyl
• the invention also provides a method of protecting an organic material susceptible to bacterial or other microbial attack which comprises treating the material with an active compound of the invention.
• the organic material may be, for instance, a natural or synthetic polymeric material, a proteinaceous or carbohydrate substance, or a natural or synthetic fibre or textile material formed therefrom.
• the invention also provides an animal feedstuff composition comprising an active compound of the invention in an amount sufficient to promote the growth of the animal fed with the composition.
• EXAMPLE 1 A mixture of 10 grams of 5-amino-4-cyano-l-methyl- 3-(5-nitro-2-furyl)-pyrazole and 100 millilitres of percent formic acid was heated under reflux for 1 hour and cooled. The crystalline solid was collected, washed with water and recrystallised from dimethylformamide. The product was 1-methyl-3-(5-nitro-2-furyl)- l H- pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300C.
• EXAMPLE 2 The procedure described in Example 1 was carried out using 5-amino-4-carbamoyll -methyl-3-(5-nitro-2- furyl)-pyrazole as'starting material instead of S-amino- 4-cyanol -methyl-3-( 5-nitro-2-furyl )-pyrazole, the reaction conditions being the same.
• the product was 1-methyl-3-(5-nitro-2-furyl)-1H- pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300C., identical with the product obtained in Example 1.
• EXAMPLE 3 A mixture of 0.2 grams of 5-amino-4-carbamoyl-lmethyl-3-(5-nitro-2-furyl)-pyrazole and 5.0 millilitres of triethylorthofonnate was heated under reflux for 3 hours and cooled. The crystalline solid was collected, washed with ethanol and dried. The product was 1- methyl-3-(5-nitro-2-furyl)- l H-pyrazolol 3 ,4- d]pyrimidin-4(5H)-one having melting point 300C.
• EXAMPLE 4 The procedure described in Example 1 was carried out using 5-amino-4-cyano-l-isopropyl-3-(5-nitro-2- furyl)-pyrazole as starting material instead of S-amino- 4-cyano-l-methyl-3-(5-nitro 2-furyl)-py razole, the reaction conditions being the same.
• EXAMPLE 5 The procedure described in Example 1 was carried out using 5-amino-4-cyano-3-(5-nitro-2-furyl)-l-npentyl-pyrazole as starting material instead of S-amino- 4-cyano-l-methyl-3-(5-nitro-2-furyl)-pyrazole, the reaction conditions being the same.
• the product was 3-(5-nitro-2-furyl)-l-n-pentyl-lH- pyrazolo[ 3 ,4-d ]pyn'midin-4( SH )-one.
• EXAMPLE 6 A mixture of 10 grams of 5-amino-4-carbamoyl-lmethyl-3-(5-nitro-2-furyl)-pyrazole and 100 millilitres of acetic anhydride was heated under reflux for 6 hours and cooled. The crystalline solid was collected, washed with alcohol and recrystallised from dimethylformamide.
• the product was l,6-dimethyl-3-(5nitro-2-furyl)- 1H-pyrazolo[3,4-d]pyrimidin-4(5l-I)-one which has melting point 300C.
• the product was l-methyl-6-(1-propenyl)-3-(5- nitro-2-furyl)-1l-l-pyrazoloI3,4-d1pyrimidin-4- (l-l)-one, which has melting point 300C.
• the product was 6-chloromethyl-l-methyl-3-(5- nitro-2-t'uryl)-1H-pyrazolo[3 ,4-d1pyrimidin-4- (5H)-one, which has melting point 300C. with decomposition.
• the product was 6-cyclohexyl-1-methyl-3-(5-nitro-2- furyl)-1l-l-pyrazolo[3 ,4-d pyrimidin-4-( 5H )-one, which has melting point 300C.
• the product was 6-benzyl-l-methyl-3-(5-nitro-2- furyl)-lH-pyrazolo[3,4-d]pyrimidin-4(5H)-one, which has melting point 300C.
• EXAMPLE 1 l EXAMPLE 12 The procedure described in Example 1 l was carried out using crotonic anhydride as starting material instead of propionic anhydride, the reaction conditions being the same.
• the product was 1-methyl-3-(5-nitro-2-furyl)-6-(lpropenyl l l-l-pyrazolo[3 ,4-d ]pyrimidin-4( 5 H )-one having melting point 300C.
• the product was 1-methyl-3-(5-nitro-2-furyl)-6- propyl-lH-pyrazol0[3,4-d]pyrimidin-4(5l-l)-one, having melting point 300C.
• EXAMPLE 15 A mixture of 11.6 grams of 5-amino-4-cyano-1- ethoxycarbonyl-3(5-nitro-2-furyl)-pyrazole, 4.1 grams of acetic anhydride and 2.0 grams of concentrated sulphuric acid (S.G. 1.84) was heated under reflux for 3 hours. The solid product which formed during reaction was collected by filtration, washed with ether and dried. Recrystallisation from dimethylformamide gave 1 -ethoxycarbonyl-6-methyl-3-( S-nitro-Z-furyl l H pyrazolo[3,4-d]pyrimidin-4(5H)-one, having decomposition point 296C.
• EXAMPLE 16 The procedure described in Example 1 l was carried out using chloroacetic anhydride as starting material instead of propionic anhydride, the reaction conditions being otherwise essentially the same.
• the product was 6-chloromethyll -methyl-3-( 5-nitro2-furyl 1 H- pyrazolo[3,4-d]pyrimidin-4(5H)-one, having melting point 300C. with decomposition.
• EXAMPLE 17 A mixture of 2.3 grams of 5-amino-4-cyano-lmethyl-3-(5-nitro-2-furyl)-pyrazole, 15 millilitres of dimethylformamide, 15 millilitres of anhydrous pyridine and 0.8 grams of acetyl chloride was heated under reflux for 2 hours and cooled. The mixture was diluted with 50 millilitres of ice-water and the solid which precipitated was collected, washed with water and dried. Recrystallisation from aqueous dimethylformamide gave 5-acetamido-4-cyano-l -methyl-3-( 5-nitro-2- furyl)-pyrazole having melting point 250C.
• EXAMPLE 18 a The procedure described in Example 17 was carried out using hexahydrobenzoyl chloride as starting material instead of acetyl chloride, the reaction conditions being the same.
• the product was 4-cyano-5-hexahydrobenzamido-1- methyl-3-(5-nitro-2-furyl)-pyrazde, having melting point 234C.
• EXAMPLE 19 A mixture of 11.6 grams of 5-amino-4-cyano-lmethyl-3-(5-nitro-2-furyl)-pyrazole, 7.7 grams of phenylacetyl chloride, 50 millilitres of dimethylformamide and 30 millilitres of anhydrous pyridine was heated under reflux for 4 hours and cooled. The mixture was then diluted with 100 millilitres of ice-water and a crude solid was obtained. A mixture of this solid with millilitres of dimethylforrnamide and 10 millilitres of concentrated sulphuric acid (S.G. 1.84) was heated under reflux for 30 minutes and cooled.
• S.G. 1.84 concentrated sulphuric acid
• EXAMPLE 20 The procedure described in Example was carried out using 5-arnino-4-cyano-1-n-propyl-3-(5-nitro-2- furyl)-pyrazole as starting material instead of S-amino- 4-cyano- 1 -ethoxycarbonyl-3 5-nitro-2-furyl pyrazole.
• the product was 6-methyl-l-n-propyl-3-(5-nitro-2- furyl l H-pyrazole[3 ,4-d]pyrimidin-4( 5H one, having melting point 276C.
• EXAMPLE 21 Preparation of Tablets 100 g of l-methyl-3-(5-nitro-2-furyl)-IH-pyrazolo [3,4-d]pyrimidin-4(5H)-one are mixed with 60.0 g of maize starch and 35.0 g of lactose, the mixture is moistened with a solution of 5.0 g of gelatin and 3.0 g of glycerol in 70.0 g of water and granulated through a sieve. The granulate is mixed with a mixture of 15.0 g of talcum, 10.0 g of maize starch and 2.0 g of magnesium stearate. The resulting mixture is pressed into 1,000 tablets, each containing 100 mg of active substance. If desired, the tablets can be grooved for better adaption of the dosage.
• the active substance and the colloidal silicon dioxide are passed through a sieve of 1.2 mm mesh diameter (1).
• the p-hydroxybenzoic acid esters, the citric acid and the sodium cyclamate are dissolved in the given amount of boiling distilled water; the glycerol is then added to this solution (II).
• the sodium carboxymethyl cellulose and the sugar are thoroughly mixed (III).
• composition III is then added at C to Solution II under stirring until complete dissolution of III.
• the viscous, slightly turbid liquid is cooled to room temperature, filtered, if necessary, and mixed with composition I.
• Water is added to the resulting mixture up to the prescribed weight of 1,155.0 g and the syrup obtained is homogenized.
• R is alkyl having from one to five carbon atoms or carbalkoxy having from one to 'five carbon atoms in the alkyl moiety
• R is hydrogen, alkyl having from one to five carbon atoms which may be unsubstituted or substituted by chloro or bromo; cycloalkyl having from five to seven carbon atoms in the carbocyclic ring, benzyl, phenylethyl, naphthylmethyl, or alkenyl having from two to four carbon atoms.
• a compound according to claim 1 which is lmethyl-3-(5-nitro-2furyl)-lH-pyrazoi0 ⁇ 3,4-d] pyrimidin-4(5l-l)-one.
• a compound according to claim 1 which is isopropyl-3 5 -nitro-2-furyl)-1H-pyrazolo[3 ,4- d]pyrimidin-4(5H)-one.
• a compound according to claim 1 which is 3-(5- nitro-Z-furyD-l-n-pentyl-1H-pyrazolo[3,4-

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Earth Drilling (AREA)
• Plural Heterocyclic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Catalysts (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=27448964

Family Applications (2)

Family Applications Before (1)

Country Status (17)

Cited By (5)

Families Citing this family (7)

Citations (3)

Family Cites Families (3)

• 0
  • BE BE758050D patent/BE758050A/xx unknown
• 1969
  • 1969-10-28 GB GB5266369A patent/GB1326360A/en not_active Expired
• 1970
  • 1970-10-12 CH CH1873772A patent/CH549598A/xx not_active IP Right Cessation
  • 1970-10-12 CH CH1873572A patent/CH572053A5/xx not_active IP Right Cessation
  • 1970-10-12 CH CH1873872A patent/CH549599A/xx not_active IP Right Cessation
  • 1970-10-12 CH CH1496870A patent/CH548412A/xx not_active IP Right Cessation
  • 1970-10-12 CH CH1873672A patent/CH549597A/xx not_active IP Right Cessation
  • 1970-10-21 NL NL7015412A patent/NL7015412A/xx not_active Application Discontinuation
  • 1970-10-21 DK DK535970AA patent/DK130589B/da unknown
  • 1970-10-21 SE SE7014182A patent/SE383747B/xx unknown
  • 1970-10-21 NO NO03985/70A patent/NO130007B/no unknown
  • 1970-10-27 AT AT472471A patent/AT305994B/de not_active IP Right Cessation
  • 1970-10-27 AT AT472171A patent/AT303714B/de not_active IP Right Cessation
  • 1970-10-27 US US00084512A patent/US3716555A/en not_active Expired - Lifetime
  • 1970-10-27 IE IE1371/70A patent/IE34623B1/xx unknown
  • 1970-10-27 AT AT472371A patent/AT303715B/de not_active IP Right Cessation
  • 1970-10-27 FR FR707038696A patent/FR2070170B1/fr not_active Expired
  • 1970-10-27 AT AT963670A patent/AT299179B/de active
  • 1970-10-27 US US00084531A patent/US3755324A/en not_active Expired - Lifetime
  • 1970-10-27 DE DE19702052719 patent/DE2052719A1/de active Pending
  • 1970-10-27 AT AT472571A patent/AT304518B/de not_active IP Right Cessation
  • 1970-10-27 RO RO64798A patent/RO56795A/ro unknown
  • 1970-10-27 IL IL35542A patent/IL35542A/xx unknown
  • 1970-10-27 DE DE19702064874 patent/DE2064874A1/de active Pending
  • 1970-10-27 AT AT472671A patent/AT304519B/de not_active IP Right Cessation
  • 1970-10-27 AT AT472271A patent/AT304517B/de not_active IP Right Cessation
  • 1970-10-27 BG BG015927A patent/BG17005A3/xx unknown
• 1974
  • 1974-01-17 SE SE7400605A patent/SE402591B/xx unknown
• 1976
  • 1976-05-31 KE KE2638*UA patent/KE2638A/xx unknown
  • 1976-08-19 HK HK520/76*UA patent/HK52076A/xx unknown

Patent Citations (3)

Also Published As

Similar Documents